Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study.
Everhart RS, McWilliams E, Maggs J, Sawicki GS, Sconiers T, Smith K, Yablon D, Butcher J, Prickett M, Bacon C, Goodman A, Gifford AH, Mayer-Hamblett N, Nichols DP, Riekert KA. Everhart RS, et al. Among authors: sawicki gs. J Cyst Fibros. 2024 Nov 21:S1569-1993(24)01811-3. doi: 10.1016/j.jcf.2024.11.003. Online ahead of print. J Cyst Fibros. 2024. PMID: 39578180
Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial.
Gifford AH, Odem-Davis K, Kloster M, O'Sullivan BP, Omlor GJ, Millard SL, Clancy JP, Sawicki GS, Riekert K, Mayer-Hamblett N, Nichols DP; SIMPLIFY Study Group. Gifford AH, et al. Among authors: sawicki gs. J Cyst Fibros. 2024 Sep 14:S1569-1993(24)00839-7. doi: 10.1016/j.jcf.2024.08.008. Online ahead of print. J Cyst Fibros. 2024. PMID: 39278759
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.
Mayer-Hamblett N, Nichols DP, Odem-Davis K, Riekert KA, Sawicki GS, Donaldson SH, Ratjen F, Konstan MW, Simon N, Rosenbluth DB, Retsch-Bogart G, Clancy JP, VanDalfsen JM, Buckingham R, Gifford AH. Mayer-Hamblett N, et al. Among authors: sawicki gs. Ann Am Thorac Soc. 2021 Aug;18(8):1397-1405. doi: 10.1513/AnnalsATS.202010-1336SD. Ann Am Thorac Soc. 2021. PMID: 33465316 Free PMC article.
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Mayer-Hamblett N, et al. Among authors: sawicki gs. Ann Am Thorac Soc. 2024 Nov;21(11):1507-1515. doi: 10.1513/AnnalsATS.202404-366OC. Ann Am Thorac Soc. 2024. PMID: 39041864 Clinical Trial.
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study.
Maggs J, Sawicki GS, Bacon C, McWilliams E, Yablon D, Ertman B, Sweeney L, Butcher JL, Everhart RS, Prickett M, Siracusa C, Gifford AH, Mayer-Hamblett N, Nichols DP, Goodman A, Woo T, Riekert KA. Maggs J, et al. Among authors: sawicki gs. Contemp Clin Trials. 2025 Jan;148:107752. doi: 10.1016/j.cct.2024.107752. Epub 2024 Nov 17. Contemp Clin Trials. 2025. PMID: 39557157 Clinical Trial.
Cross-Cutting mHealth Behavior Change Techniques to Support Treatment Adherence and Self-Management of Complex Medical Conditions: Systematic Review.
Eaton CK, McWilliams E, Yablon D, Kesim I, Ge R, Mirus K, Sconiers T, Donkoh A, Lawrence M, George C, Morrison ML, Muther E, Oates GR, Sathe M, Sawicki GS, Snell C, Riekert K. Eaton CK, et al. Among authors: sawicki gs. JMIR Mhealth Uhealth. 2024 May 1;12:e49024. doi: 10.2196/49024. JMIR Mhealth Uhealth. 2024. PMID: 38717433 Free PMC article. Review.
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH; SIMPLIFY Study Group. Mayer-Hamblett N, et al. Among authors: sawicki gs. Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4. Lancet Respir Med. 2023. PMID: 36343646 Free PMC article. Clinical Trial.
244 results